co mmentar y calcification. As can be seen from the anatomy of the auricle, the presence of chondrocytes does not necessarily mean the development of endochondral bone formation. Furthermore, calcified and non-calcified portions are clearly separate in the bone. Thus, the time course needs to be demonstrated, and the initial mechanisms that trigger the transition from cartilage to bone tissue within the vessel wall need to be identified.
If medial calcification also involves the processes of endochondral bone formation, another major issue remains to be clarified. What are the essential differences in the pathogenesis of calcification in the intima and in the media? Because medial calcification is often seen in the elderly and in patients with CKD or diabetes, a number of factors have been examined, such as uremic toxins, oxidative stress, and inflammation; however, they fail to explain the differences clearly. Future breakthroughs are certainly required to establish effective prevention and treatment modalities for medial calcification in CKD patients.
Can we do better than a single estimated GFR threshold when screening for chronic kidney disease? ED The publication of the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines by the National Kidney Foundation (NKF) in 2002 provided the medical community for the first time with a uniform definition of chronic kidney disease (CKD). 1 These guidelines had the objective of timely management and treatment of this population at risk for increased mortality. This classification of CKD is based on three fundamental components: (1) an anatomical or structural component as evidenced by the presence of parenchymal renal disease (for example, abnormal imaging testing, abnormalities of the urine composition, and so on); (2) a temporal component in which the abnormalities are present for at least 3 months; and (3) a functional component based on glomerular filtration rate (GFR). Although all three are critical, the level of GFR is the pivot for staging the disease and determining the applicability of the recommended KDOQI treatment and management guidelines. Because direct GFR measurements are expensive and inconvenient, estimated GFR (eGFR) by the abbreviated Modification of Diet in Renal Disease (MDRD) equation has been the tool chosen by the NKF. 1 An important consideration is that these guidelines define and classify CKD irrespective of cause of renal disease and make no distinction based on gender and age. 2 For example, patients with stage 3 CKD (eGFR 30-59 ml/min/1.73 m 2 ) are lumped together even though they represent a wide spectrum of 'disease' from a 35-year-old man with a progressive glomerulonephritis to a 65-year-old woman without risk factors for CKD but with a high-normal serum creatinine level.
The MDRD equation was developed from nephrology referral patients identified by an elevated serum creatinine level (≥1.2 mg/dl in women and ≥1.4 mg/dl in men). 3 To emphasize an early diagnosis of CKD, the NKF and the National Kidney Disease Education Program (NKDEP) generalized the use of the equation and recommend that all laboratories automatically report an eGFR with each serum creatinine test measured, irrespective of the clinical setting in which the test has been co m m e nt a r y ordered. Thus, the MDRD equation is implicitly being used as a screening tool to detect CKD in the general population, most of whom are normal healthy people. Although this equation has been found to perform very well in patients with elevated serum creatinine levels, this tool underestimates GFR in populations characterized by normal serum creatinine levels. 4, 5 Recognizing limitations in the application of the MDRD equation as a screening test, the NKF and NKDEP recommend reporting exact eGFR values if the eGFR is below 60 ml/min/1.73 m 2 , and limiting the report to '>60 ml/min/1.73 m 2 ' if it is above this cutoff value. 6 When screening for disease, it is important to recognize that health is a relative condition that does not have a universally accepted definition. There are generally two approaches used to define disease thresholds: the first is the 'critical value' at which increased morbidity and mortality occur, and the second is the 'healthassociated reference value. ' 7 In this issue of Kidney International, Wetzels et al. 8 use this latter approach by defining reference values for eGFR based on the MDRD equation using a cross-sectional sample of a healthy population in the Netherlands. The authors report that a significant minority of healthy subjects, mostly older and female subjects, have indeed an eGFR below 60 ml/min/1.73 m 2 , the recommended cutoff to categorize a subject as having CKD. Conversely, many younger, and particularly male, subjects have a threshold above 60 ml/min/1.73 m 2 . Importantly, the authors calibrated the creatinine values obtained by their laboratory to the one used by the original MDRD laboratory to minimize bias.
The result of this work questions the definition of CKD solely based on an eGFR of less than 60 ml/min/1.73 m 2 irrespective of age or clinical setting. As shown in Table  1 , the age-and sex-specific lower limit of normal for eGFR (5 th percentile) in the study by Wetzels et al. 8 is equivalent to the sex-specific upper limit of normal (95 th percentile) for serum creatinine (1.3 mg/dl in men and 1.1 mg/dl in women for ages less than 70 years). This is a very similar threshold to that used to identify the participants for deriving the MDRD equation. This is also consistent with studies using kidney donors to represent health, in that the upper limit of normal for serum creatinine did not vary with age and was approximately 0.2 mg/dl higher in men than in women. 9 After age 70 years, when occult disease is highly prevalent, a questionnaire, such as that used by Wetzels et al., 8 to classify health may be inadequate, and the upper limit of normal for serum creatinine is less clear.
This contrasts with the setting of care for patients with known and established kidney disease, where information regarding the severity of kidney dysfunction by eGFR is more useful than serum creatinine alone. The improved performance of the MDRD equation in this setting is largely due to the statistical modeling of muscle mass with the surrogate markers: age, sex, and race. In contrast, when the MDRD equation is used to screen patients for CKD, the equation is inherently flawed, because age, sex, and race are not simply surrogate markers of muscle mass, but also markers of CKD risk. One could argue that, for the care of a healthy subject with no identifiable risk factors for CKD and no blood or urine chemistry abnormalities, exact knowledge of the degree of GFR is not clinically crucial. The current recommendation by the NKF is to report exact values only when below 60 ml/min/1.73 m 2 , but this approach is circular, because the clinician has already assumed the patient has CKD by applying the MDRD equation (Figure 1a) . 10, 11 A more defensible position proposed by Wetzels et al. 8 is to use a reference-value eGFR to define CKD, because eGFR levels below the lower reference threshold are much less plausible (Figure 1b ). There are two important caveats to consider. First, the lower limit of normal for MDRD equation eGFR is substantially different from the lower limit of normal for a direct GFR measurement. For example, by MDRD eGFR, Wetzels et al. 8 found the lower limit of normal (5 th percentile) to be 72-77 ml/min/1.73 m 2 in a 20-year-old and 51-57 ml/min/1.73 m 2 in a 65-year-old. This is far below the lower limit of normal for a direct GFR measurement of 91 ml/ min/1.73 m 2 in a 20-year-old and 69 ml/ min/1.73 m 2 in a 65-year-old, 9 because age, sex, and race inadequately model interindividual variability in muscle mass and because there are likely differences in muscle mass between healthy persons and CKD patients. 10 The second caveat is that the commonly reported upper limit of normal for serum creatinine (1.3 mg/ dl in men and 1.1 mg/dl in females) provides equivalent information (Table 1) . In essence, the proposal by Wetzels et al. 8 is similar to using serum creatinine reference values to define CKD. Nevertheless, the work by Wetzels et al. 8 brings up a very important point: the use of a single threshold for GFR is inappropriate to define CKD. Both longitudinal and cross-sectional studies have shown that GFR declines with normal aging by approximately 5-10 ml/min per decade. 9 As the data of Wetzels et al. 8 suggest, a significant minority of the studied population believed to be healthy would be considered to have the diagnosis of stage 3 CKD just by the sole finding of a decreased eGFR. As is pointed out above, the MDRD equation, even when calibrated serum creatinine values are used, is likely to underestimate the GFR in healthy subjects and thus increase the risk of misdiagnosing healthy subjects with CKD. It has been argued that despite inaccuracy with equations, an eGFR less than 60 ml/min/1.73 m 2 should be used to define CKD, because this 'critical value' predicts morbidity and mortality. However, recent data do not fully support this threshold. Epidemiological data derived from large managed-care populations limited to patients with multiple and stable serum creatinine levels found no increased adjusted risk of mortality in subjects with an eGFR of 50-59 ml/min/1.73 m 2 compared with subjects with an eGFR of 60 ml/min/1.73 m 2 or higher. 12, 13 In fact, in one study a stable eGFR of 50-59 ml/ min/1.73 m 2 in older subjects was associated with a lower adjusted risk of mortality than an eGFR of 60 ml/min/1.73 m 2 or higher. 13 The problem is that eGFR based on serum creatinine is itself a marker of muscle mass and thus fitness. A decreased true GFR will probably predict increased mortality, but the increased muscle mass reflected by a decreased eGFR may be protective against mortality. Moreover, recent data have also found that CKD complications (anemia, hyperphosphatemia, acidosis) are relatively uncommon in the general population for persons with an eGFR of 30-59 ml/min/1.73 m 2 . 14 In conclusion, the work by Wetzels et al. 8 provides further support for considering age-and genderspecific serum creatinine or eGFR values when screening for CKD. 
